Compelo Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More

Sequenom partners with Illumina for prenatal test

Sequenom and its subsidiaries have agreed to purchase Illumina's sequencing equipment and consumables to develop a noninvasive test - HiSeq 2000 platform - designed to detect an overabundance of chromosome 21 in pregnant women.

The companies will work collaboratively toward the submission for regulatory approval of an in vitro diagnostic product which is used to detect fetal chromosomal abnormalities.

Sequenom chairman and CEO Harry Hixson said this agreement brings trisomy test to market, gives us the scalability to address the opportunity of their noninvasive prenatal test for trisomy 21.

Illumina president and CEO Jay Flatley with the sequencing technology available, they are ready to meet Sequenom’s needs as it prepares for the commercial launch of test.